Dan Omstead

Tekla World Healthcare Fund is a closed-end management investment company, which engages in investing in the healthcare industry. Its objective is to seek current income and long-term capital appreciation through investment companies engaged in the healthcare industry, including equity securities and debt securities. The company was founded on March 5, 2015 and is headquartered in Boston, MA.

abrdn, Inc. is SEC-registered investment advisor and mutual fund manager headquartered in Philadelphia, Pennsylvania. Founded in 1995, the firm was formerly known as Aberdeen Asset Management, Inc. and as Aberdeen Standard Investments, Inc. until it became abrdn, Inc. in 2022. They are a subsidiary of abrdn Holdings Ltd., ultimately held by abrdn Plc (LON: ABDN) in Great Britain. abrdn provides investment products and solutions to various clients across the world.

Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund.

Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product

Concentric Medical, Inc. designs, manufactures and distributes medical devices. The company was founded in August 1999 and is headquartered in Kalamazoo, MI.

Magellan Diagnostics, Inc. develops diagnostic laboratory products. It products include LeadCare II System and LeadCare Ultra. The firm's services encompass blood lead and zinc protoporphyrin analysis. The company was founded in 1968 and is headquartered in North Billerica, MA.

Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA.

Elemé Medical, Inc. manufactured laser-based cellulite treatment. The firm’s products included SmoothShapes with Photomology technology, a medical device for the temporary reduction in the appearance of cellulite and SmoothLipo, a medical device for laser-assisted lipolysis that is used in body shaping and skin tightening of localized areas. The company was founded by R. Robert Nagel and was headquartered in Merrimack, NH.

CardioKinetix, Inc. develops ventricular partitioning device for heart failure disease. It develops transcatheter implant called the Parachute Ventricular Partitioning Device, which intends to treat heart failure resulting from a heart attack in patients by improving overall cardiac function. The company was founded by Alexander Khairkhahan, Serjan D. Nikolic and Hugh R. Sharkey in 2002 and is headquartered in Menlo Park, CA.

DynexCorp Ltd. provides investment advisory services. The private company is based in Geneva, Switzerland.

Palyon Medical Corp. develops medical devices for the treatment of chronic pain, spasticity and other neurological diseases. The company was founded by Greg David, David A. Present and Klaus G. Lederer on May 16, 2003 and is headquartered in Santa Clarita, CA.

Insightra Medical, Inc. develops medical devices. It offers QuickWIT, a cardiology wire insertion tool, sensiPull, an ergonomic aortic punch, and the Modulare, a catheter stabilization device. The firm also offers innovative solutions for the common disease of inguinal hernias and ventral hernia. The company was founded by Bradley J. Sharp in March 2001 and is headquartered in Irvine, CA.

Heading Home, Inc. provides emergency, transitional and permanent housing, and support services. The firm offers services to ow-income homeless and formerly homeless families and individuals in the communities of Boston, Cambridge, Somerville, Medford, Malden, Everett, Quincy, Chelsea and Revere. The company was founded in 1974 and is headquartered in Charlestown, MA.

Euthymics Bioscience, Inc. develops a novel medicine for alcohol use disorder (AUD) and smoking cessation. It engages in developing a medicine for central nervous system disorders of significant unmet medical need, including major depressive disorder (MDD) and alcohol use disorder (AUD). The firm provides Amitifadine, an antidepressant for major depressive disorder. The firm focuses on the modulation of neurotransmitters, including serotonin (5-HT), norepinephrine (NE), and dopamine (DA). The company was founded by Anthony A. McKinney and Franklin P. Bymaster in 2009 and is headquartered in Cambridge, MA.

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.

Tekla Healthcare Opportunities Fund operates as a closed-end investment fund and investment trust. The trust's investment objective is to seek current income and long-term capital appreciation through investing in companies engaged in the healthcare industry, including equity securities, debt securities and pooled investment vehicles. The Trust was founded on April 2, 2014 and is headquartered in Boston, MA.

HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA.

Tekla Income Edge Fund is a non-diversified, closed-end investment company that will engage in investment activities. It expects to invest in U.S. and non-U.S. equity and debt securities of companies in the healthcare industry, including, but not limited to, biotechnology, pharmaceutical, medical devices and healthcare services companies. The fund is headquartered in Boston, MA.

Veniti, Inc. operates as a medical device company which focuses on the treatment of venous insufficiency. Its products include VENI RF Plus which uses radio frequency generated steam to destroy problematic veins that manifest as varicose veins; VENI Vena Cava Filter system which is engineered to improve the accuracy, efficiency of deployment, placement and retrieval; and VICI Venous Stent which is designed specifically for the treatment of venous outflow obstruction. The company was founded by Sean C. Morris and Mark Klopp in 2009 and is headquartered in Fremont, CA.